OptimizeRx
OPRX
128 hedge funds and large institutions have $205M invested in OptimizeRx in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 37 increasing their positions, 41 reducing their positions, and 45 closing their positions.
871% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $1.52M
10% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 41
9.1% less ownership
Funds ownership: 85.6% → 76.5% (-9.1%)
12% less funds holding
Funds holding: 146 → 128 (-18)
40% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 45
52% less capital invested
Capital invested by funds: $426M → $205M (-$221M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$8.04M |
| 2 |
Millennium Management
New York
|
+$6.15M |
| 3 |
Two Sigma Advisers
New York
|
+$4.69M |
| 4 |
Two Sigma Investments
New York
|
+$4.08M |
| 5 |
IP
Invenire Partners
Ridgefield,
Connecticut
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$19.3M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$16.9M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$14M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$10.9M |
| 5 |
LCG
Lisanti Capital Growth
New York
|
-$4.95M |
OPRX Hedge Fund Activity: Q3 2022 in Review
128 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q3 2022, worth a combined $205M — down 52% from $426M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of OPRX and 27 opened new positions — a net loss of 18 holders — while 41 trimmed existing stakes and 37 added.
The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $8.04M. The largest seller was Artisan Partners, exiting entirely with an estimated $19.3M sold.
- 128 institutional investors held OptimizeRx (OPRX) as of Q3 2022, down from 146 in Q2 2022.
- Funds reported $205M of OptimizeRx stock for Q3 2022, down 52% quarter-over-quarter.
- 27 funds opened new OptimizeRx positions in Q3 2022 and 45 closed out, a net change of -18 holders.
- The largest OptimizeRx buyer in Q3 2022 was Kennedy Capital Management, an estimated $8.04M added.
- The largest OptimizeRx seller in Q3 2022 was Artisan Partners, an estimated $19.3M sold.
Based on aggregated 13F filings for Q3 2022.